PA-MDSLINK-INC
In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/
MaGiC-SFP 2.5™ (M ulti-Giga bit C oax S mall F orm-factor P luggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port).
Applications:
- Last 100-meter distribution using existing, in-building coax.
- Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul the traffic with MaGiC at speeds up to 2.5G in either direction.
- Hospitality/commercial wireless AP backhaul and powering. Using standalone power injectors, a single SFP/SFP+-based Ethernet switch combined with the MaGiC SFP can provide both data and power to remote APs in hallways, hotel rooms, public spaces and meeting rooms.
- Point-to-point (P2P), building-to-building or in-building. Using two media converters with two MaGiC SFP’s to deliver up to 2.5 Gbps over coax in a point-to-point setting.
MaGiC has a maximum packet error rate (PER) of 1e-6/1e-8 with a latency of six ms.
Channel stacking allows the delivery of up to 4 Gbps on a single coax wire by using high and low frequency MaGiC SFP’s.
Roadmap to the next generation MoCA Access 3.0 standard provides a smooth transition to 10 Gbps with backward interoperability with MoCA Access 2.5/2.0.
“Increasing the capacity of last mile data services is expensive. Existing solutions either call for new cable/fiber installation, or simply don’t meet the ever-increasing demand for bandwidth at reasonable prices increments," said Jim Luciano, president and founder of MDSLink.
MaGiC works in all telco/fiber, cable and satellite environments and is available now.
Contact the following distributors for more information including pricing: PCT International (Phoenix, AZ, https://www.pctinternational.com ); SWG in Scranton, PA (https://swginc.com ); GZT Telkom-Telmor Sp. z o.o., Gdansk, Poland, www.telmor.pl ; and Heights Telecom www.heights-t.com , Tel Aviv, Israel.
About MDSLink
MDSLink, Inc., based in Bethlehem, PA, offers innovative products that help operators and integrators use existing, in-building wiring as the demand for high reliability and high bandwidth continues unabated. More information about the company and its products can be found at www.mdslink.com , or contact Jim Luciano, CEO, at jim.luciano@mdslink.com .
MaGiC and MaGiC SFP are trademarks of MDSLink, copyright 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005534/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release
This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
